You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 190 Identifying subgroups that benefit from ultra-radical upfront surgery in advanced epithelial ovarian cancer: auxiliary data from the Stockholm ovarian cancer project

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
06. Ovarian cancer
190 Identifying subgroups that benefit from ultra-radical upfront surgery in advanced epithelial ovarian cancer: auxiliary data from the Stockholm ovarian cancer project
  1. Nina Groes Kofoed1,2,
  2. Henrik Falconer1,2,
  3. Oscar Peñaloza2,
  4. Matteo Bottai3 and
  5. Sahar Salehi1,2
  1. 1Department of Women’s and Children’s Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Stockholm, Sweden
  2. 2Department of Pelvic Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
  3. 3Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

Abstract

Introduction/Background We previously reported that a shift to upfront ultra-radical surgery in a public health care setting increased complete macroscopic resection (CMR) rates without improving survival in women with advanced epithelial ovarian cancer (EOC). Still, CMR conferred the longest survival both before and after this shift. This paradox is likely explained by subgroups of women who may or may not benefit from increased surgical proficiency. Our objective was to identify these subgroups.

Methodology This cohort study included all women diagnosed with EOC between 2009–2011 and 2014–2016, in the Stockholm/Gotland region, Sweden. The latter cohort was exposed to the upfront ultra-radical surgical treatment algorithm. The association between surgical extent defined by a surgical complexity score (SCS) and overall survival (OS) was analyzed with Cox regression models.

Results The final analysis included 272 women with CMR and 150 women receiving chemotherapy only. Exposed women with stage III had an improved OS after 5-years, Hazard Ratio (HR) 0.37 (95% CI, 0.16–0.85); p=0.02, in contrast to stage IV, HR 1.23 (95% CI, 0.72–2.11); p=0.44.

Exposed women where CMR was achieved with a low/medium SCS had an improved OS, adjusted HR (aHR) 0.56 (95% CI, 0.33–0.96); p=0.03 contrary to when a high SCS was required, aHR 0.84 (95% CI, 0.40–1.75); p=0.63. There was no absolute difference in 5-year OS in women with stage IV where a high SCS was needed to achieve CMR vs. the alternative (chemotherapy only), 5.7% (95% CI, -4.3 to 15.7).

Conclusion With longer follow-up, an upfront ultra-radical treatment algorithm improves OS in women with stage III EOC and in whom CMR was achieved with a low/medium SCS. The effect of cytoreductive surgery is limited when a high SCS is required, particularly in stage IV. Clinical trials are warranted to investigate the effect of surgical resection altogether in this subgroup.

Disclosures Nina Groes Kofoed, Oscar Peñaloza, Matteo Bottai and Sahar Salehi declare no conflict of interest, Henrik Falconer declares the potential conflict of interest; ‘receipt of honoraria or consultation fees’ from Surgical Science.

https://doi.org/10.1136/ijgc-2024-ESGO.587

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.